Surgical Oncology-Oxford最新文献

{"title":"Clinical outcomes of bilobed platysma myocutaneous flap technique with neck dissection in lower lip squamous cell carcinoma","authors":"Ovunc Akdemir ,&nbsp;Atilla Adnan Eyuboglu ,&nbsp;William Lineaweaver ,&nbsp;Feng Zhang","doi":"10.1016/j.suronc.2024.102130","DOIUrl":"10.1016/j.suronc.2024.102130","url":null,"abstract":"<div><h3>Background</h3><p>Squamous cell carcinoma (SCC) in the lower lip is among the most frequently encountered types of cancer. As the size of this cancer increases, the need for reconstruction becomes evident, posing a significant challenge. Depending on the staging results in these patients, neck dissection may be recommended.</p></div><div><h3>Objective</h3><p>This study aims to demonstrate the successful application or feasibility of our Bilobed Platysma Myocutaneous Flap technique in patients with lower lip SCC.</p></div><div><h3>Methods</h3><p>The Bilobed Platysma Myocutaneous Flap was applied to all patients. Following TNM staging, supraomohyoid and/or radical neck dissection were performed. Surveys were conducted with the patients, and scoring was implemented based on the results for evaluation.</p></div><div><h3>Results</h3><p>Between 2014 and 2018, 23 patients underwent treatment with this flap, and all flaps survived. Among these patients, bilateral supraomohyoid neck dissection was performed on 14, while modified radical neck dissection on one side and supraomohyoid neck dissection on the other side were conducted on the remaining 9 patients. Throughout the 5-year follow-up period, no recurrence was observed in the patients.</p></div><div><h3>Conclusion</h3><p>The combination of the Bilobed Platysma Myocutaneous Flap technique and neck dissection can be successfully employed in the reconstruction and treatment of lower lip cancers.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142167527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes after breast cancer liver metastasis surgery: A European, retrospective, snapshot study (LIBREAST STUDY)","authors":"Miguel Cantalejo-Díaz ,&nbsp;José M. Ramia ,&nbsp;Iñaki Álvarez-Busto ,&nbsp;Balint Kokas ,&nbsp;Gerardo Blanco-Fernández ,&nbsp;Elena Muñoz-Forner ,&nbsp;Attila Oláh ,&nbsp;Eva Montalvá-Orón ,&nbsp;Víctor López-López ,&nbsp;Fernando Rotellar ,&nbsp;Hasan Eker ,&nbsp;Arjen Rijken ,&nbsp;Mikel Prieto-Calvo ,&nbsp;Fabrizio Romano ,&nbsp;Paola Melgar ,&nbsp;Nikolaos Machairas ,&nbsp;Semra Demirli Atici ,&nbsp;Maria Jesús Castro-Santiago ,&nbsp;Mickaël Lesurtel ,&nbsp;Michal Skalski ,&nbsp;Mario Serradilla-Martín","doi":"10.1016/j.suronc.2024.102129","DOIUrl":"10.1016/j.suronc.2024.102129","url":null,"abstract":"<div><h3>Introduction</h3><p>Breast cancer (BC) is the most common malignant tumor in women. Between 20 % and 30 % of patients develop metastases from BC, 50 % of them in the liver. The mean survival rate reported in patients with liver metastases from BC (LMBC) ranges from 3 to 29 months. The role of surgery in LMBC is not clearly defined. The objective of the present study was to determine the long-term survival and disease-free survival of patients undergoing surgery for LMBC and to identify the patients who most likely benefit from surgery.</p></div><div><h3>Material and methods</h3><p>This retrospective multicenter cohort study included all consecutive patients undergoing LMBC surgery at the participating European centers from January 1, 2010, to December 31, 2015. The <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> ID is NCT04817813.</p></div><div><h3>Results</h3><p>A hundred women (mean age 52.6 years) undergoing LMBC surgery were included. Five-year disease-free survival was 29 %, and 5-year overall survival was 60 %. Median survival after BC surgery was 12.4 years, and after LMBC surgery, 7 years. Patients with ECOG 1, ASA score I-II, metachronous LMBC, positive hormone receptors, and who had received neoadjuvant and adjuvant hormone treatment obtained the best overall and disease-free survival results.</p></div><div><h3>Conclusions</h3><p>In cases of correct patient selection and as part of a comprehensive onco-surgical strategy, surgery for LMBC improves overall long-term survival. In our series, certain factors were linked to better disease-free and overall survival; consideration of these factors could improve the selection of the best candidates for LMBC surgery.</p></div><div><h3>Clinicaltrials.gov id</h3><p>NCT04817813.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiological and pathological predictors of post-operative upstaging of breast ductal carcinoma in situ (DCIS) to invasive ductal carcinoma and lymph-nodes metastasis; a potential algorithm for node surgical de-escalation","authors":"Gianluca Vanni ,&nbsp;Marco Pellicciaro ,&nbsp;Marco Materazzo ,&nbsp;Massimiliano Berretta ,&nbsp;Rosaria Meucci ,&nbsp;Tommaso Perretta ,&nbsp;Ilaria Portarena ,&nbsp;Chiara Adriana Pistolese ,&nbsp;Oreste Claudio Buonomo","doi":"10.1016/j.suronc.2024.102128","DOIUrl":"10.1016/j.suronc.2024.102128","url":null,"abstract":"<div><h3>Background/aim</h3><p>Ductal carcinoma in situ is considered a local disease with no metastatic potential, thus sentinel lymph node biopsy (SLNB) may be deemed an overtreatment. SLNB should be reserved for patients with invasive cancer, even though the risk of upstaging rises to 25 %. We aimed to identify clinicopathological predictors of post-operative upstaging in invasive carcinoma.</p></div><div><h3>Methods</h3><p>We retrospectively analyzed patients with a pre-operative diagnosis of DCIS subjected to breast surgery between January 2017 to December 2021, and evaluated at the Breast Unit of PTV (Policlinico Tor Vergata, Rome).</p></div><div><h3>Results</h3><p>Out of 267 patients diagnosed with DCIS, 33(12.4 %) received a diagnosis upstaging and 9(3.37 %) patients presented with sentinel lymph node (SLN) metastasis. In multivariate analysis, grade 3 tumor (OR 1.9; 95 % CI 1.2–5.6), dense nodule at mammography (OR 1.3; 95 % CI 1.1–2.6) and presence of a solid nodule at ultrasonography (OR 1.5; 95 % CI 1.2–2.6) were independent upstaging predictors. Differently, the independent predictors for SLNB metastasis were: upstaging (OR 2.1.; 95 % CI 1.2–4.6; <em>p</em> = 0.0079) and age between 40 and 6<em>0</em>yrs (OR 1.4; 95 % CI 1.4–2.7; <em>p</em> = 0.027).</p><p>All 9 patients with SLN metastasis received a diagnosis upstaging and were aged between 40 and 60 years old.</p></div><div><h3>Conclusion</h3><p>We identified pre-operative independent predictors of upstaging to invasive ductal carcinoma. The combined use of different predictors in an algorithm for surgical treatments of DCIS could reduce the numbers of unnecessary SLNB.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960740424000963/pdfft?md5=e790b0f586229fff40f722ea74640c3a&pid=1-s2.0-S0960740424000963-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant therapy for melanoma: past, present, and future","authors":"Aaron D. Therien ,&nbsp;Chinecherem M. Chime-Eze ,&nbsp;Kristen E. Rhodin ,&nbsp;Georgia M. Beasley","doi":"10.1016/j.suronc.2024.102127","DOIUrl":"10.1016/j.suronc.2024.102127","url":null,"abstract":"<div><p>Modern systemic therapy has dramatically improved outcomes for many patients with advanced metastatic melanoma. The success of these therapies has attracted much scientific interest while these therapies have made their way into the treatment of earlier stages of disease. Randomized trials have led to the approval of adjuvant immunotherapy and targeted therapy for resected stage III melanoma. However, most recently, these therapies have gained traction in the neoadjuvant setting. Promising early results led to randomized controlled trials that have now established neoadjuvant therapy as standard of care in advanced melanoma patients. Questions remain regarding the optimal choice of therapy, duration and timing of neoadjuvant therapy, extent of surgery, and the need for additional adjuvant therapy for patients who received neoadjuvant therapy. Herein we provide an overview of neoadjuvant therapy for melanoma and dilemmas to its broader applications.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960740424000951/pdfft?md5=f3254448f0caf20de2d8b5ebf495e330&pid=1-s2.0-S0960740424000951-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphocyte-to-monocyte, platelet-to-albumin and platelet-to-lymphocyte ratios as prognostic biomarkers for neoadjuvant treatment response in rectal cancer patients","authors":"V. Făgărășan ,&nbsp;V. Bințințan ,&nbsp;R. Seicean ,&nbsp;A. Caziuc ,&nbsp;R. AIlioaie ,&nbsp;G. Făgărășan ,&nbsp;A. Ilie-Ene ,&nbsp;G. Dindelegan ,&nbsp;C. Căinap","doi":"10.1016/j.suronc.2024.102126","DOIUrl":"10.1016/j.suronc.2024.102126","url":null,"abstract":"<div><h3>Introduction</h3><p>Systemic inflammatory response (SIR) indicators are an emerging category of serum biomarkers with significant potential as prognostic and predictive factors in various types of cancers The primary focus of our study was to determine the prognostic value of the lymphocyte-to-monocyte ratio (LMR), platelet-to-albumin ratio (PLR) and platelet-to-albumin ratio (PAR) in evaluating the response to neoadjuvant treatment for patients with rectal cancer.</p></div><div><h3>Materials and methods</h3><p>We included 99 consecutive patients with rectal cancer which were admitted for surgery in our institution after completing a standard neoadjuvant radio-chemotherapy regimen. Several hematologic parameters, including LMR, PAR and PLR, were calculated by collecting and analyzing blood samples preoperatively. Cases were divided into groups using ROC curve analysis to determine optimal cutoff values for each of the investigated parameters. Treatment response was assessed through histopathological analysis of the resected specimens.</p></div><div><h3>Results</h3><p>PLR values over 215.2 were correlated with the presence of lymph node metastasis. A similar correlation was observed between PAR values over 41.89 and lymph node positivity. A significant correlation was observed between the presence of tumor budding on histopathological analysis and high-PAR values. A statistically significant correlation between a high PLR and a good response to neoadjuvant treatment was determined.</p></div><div><h3>Conclusions</h3><p>High PLR values may be associated with a more favorable treatment response to neoadjuvant radio-chemotherapy. A high PAR may be associated with unfavorable histopathological characteristics. Further studies on these readily available biomarkers are required in order to validate their clinical utility.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S096074042400094X/pdfft?md5=90de88041625739cb58473a7fbde57d1&pid=1-s2.0-S096074042400094X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular markers of proliferation, DNA repair, and immune infiltration defines high-risk subset of resectable retroperitoneal sarcomas","authors":"Nathan D. Seligson ,&nbsp;Yan W. Asmann ,&nbsp;Tariq Almerey ,&nbsp;Yaquelin Coll Zayas ,&nbsp;Mark A. Edgar ,&nbsp;Steven Attia ,&nbsp;Keith L. Knutson ,&nbsp;Sanjay P. Bagaria","doi":"10.1016/j.suronc.2024.102125","DOIUrl":"10.1016/j.suronc.2024.102125","url":null,"abstract":"<div><h3>Introduction</h3><p>For retroperitoneal sarcomas (RPS), aggressive surgical resection offers the only chance for a cure; however, 5-year survival remains below 65%. Therefore, there is a critical need to identify drivers of poor clinical outcomes.</p></div><div><h3>Materials and methods</h3><p>To identify biomarkers of tumors likely to recur following curative intent resection, we performed genomic and transcriptomic sequencing for 47 and 34 patients, respectively, with non-metastatic RPS at a single, high-volume sarcoma center.</p></div><div><h3>Results</h3><p>At the DNA level, alterations in <em>TERT</em> were associated with poor disease-free survival (DFS) and overall survival (OS). Increased RNA expression of gene sets related to growth signaling and DNA repair were associated with poor DFS and OS. Infiltration of CD8⁺ T-Cells and activated dendritic cells were associated with poor DFS and OS.</p></div><div><h3>Conclusion</h3><p>These findings may help to better identify and treat non-metastatic, high-risk RPS.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer-related lymphedema: A critical review on recent progress","authors":"Nasrin Sharifi ,&nbsp;Sarfraz Ahmad","doi":"10.1016/j.suronc.2024.102124","DOIUrl":"10.1016/j.suronc.2024.102124","url":null,"abstract":"<div><p>Lymphedema is a chronic and debilitating condition characterized by an abnormal buildup of protein-rich fluid in the interstitial tissue, leading to the development of edema and tissue structural alterations. Breast cancer-related lymphedema (BCRL) remains a significant healthcare burden because it can develop within days and up to 11-years after the surgery. Specifically, axillary lymph node dissection leads to 30–50 % upper limb lymphedema, which involves the accumulation of protein-rich fluid. In this article, we provide a comprehensive/critical overview of post-mastectomy lymphedema, focusing on key aspects as diagnosis, prevention, and treatment methods. Beginning with clinical condition, the article explores the pathophysiology and risk factors associated with post-mastectomy lymphedema. It further delves into various diagnostic modalities available, highlighting the importance of early detection for optimal management of BCRL. We also examine preventive strategies, emphasizing the role of patient education, lifestyle modifications, and proactive measures in reducing the risk of lymphedema development. In terms of treatment, the article covers a wide array of interventions ranging from conservative approaches like manual lymphatic drainage and compression therapy to surgical techniques such as lymph node transfer and lymphaticovenular anastomosis. Thus, through a comprehensive synthesis of current evidence and clinical practices updates, the review aims to guide healthcare professionals in delivering preventive and effective care while improving outcomes for individuals affected by post-mastectomy lymphedema.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142087887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between preoperative appendiceal histology grade and Pseudomyxoma peritonei grade offers a solution to avoid right hemicolectomy during cytoreductive surgery and HIPEC","authors":"Richard Ghandour ,&nbsp;Armelle Bardier ,&nbsp;Mathilde Wagner ,&nbsp;Brice Malgras ,&nbsp;Rachid Kaci ,&nbsp;Solène Doat ,&nbsp;Marc Pocard","doi":"10.1016/j.suronc.2024.102123","DOIUrl":"10.1016/j.suronc.2024.102123","url":null,"abstract":"<div><h3>Introduction &amp; objectives</h3><p>Treatment of PMP consists of appendectomy, cytoreductive surgery (CRS) and HIPEC. Right-sided hemicolectomy is necessary only when PMP is high grade, given the lymphatic invasion risk. To date, no single preoperative factor was identified as predictive of PMP grade.</p></div><div><h3>Materials &amp; methods</h3><p>Preoperative factors of a prospective cohort study on PMP were retrospectively analyzed, in order to identify situations linked with high or low grade appendiceal PMP. The main outcome was PMP grade on definitive histology after CRS.</p></div><div><h3>Results</h3><p>n = 105. In univariate analysis, the grade of the appendiceal tumor, systematically reviewed in an expert center, showed an OR of 25.00 (95 % CI: 3.30–189.27; p = 0.001) and an NPV of 93.75 [85.36, 100]. Peritoneal biopsy demonstrated an OR of 19.80 (95 % CI: 2.30–170.71; p = 0.002) and a PPV of 90 [71.41, 100]. In multivariate analysis, these two factors remained significantly associated with PMP grade.</p></div><div><h3>Conclusion</h3><p>Whenever appendiceal tumor is low grade on preoperative histology, the colon has to be spared unless completeness of CRS is compromised, which is a high-grade feature in fact. In case of high grade appendiceal tumor and/or peritoneal biopsy, right-sided hemicolectomy is warranted. If no histology is available preoperatively, adapt to intraoperative lesions as no preoperative factors seem to be predictive.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of malignancy for treatment direction in patients with nonfunctioning adrenal incidentaloma","authors":"Jongwon Jung ,&nbsp;Byung-Chang Kim ,&nbsp;Douk Kwon ,&nbsp;Won Woong Kim ,&nbsp;Yu-mi Lee ,&nbsp;Kye Jin Park ,&nbsp;Seung Hun Lee ,&nbsp;Ki-Wook Chung ,&nbsp;Tae-Yon Sung","doi":"10.1016/j.suronc.2024.102122","DOIUrl":"10.1016/j.suronc.2024.102122","url":null,"abstract":"<div><h3>Background</h3><p>Adrenal incidentalomas (AI) are predominantly nonfunctional and benign, and their detection and differential diagnosis are aided by computed tomography (CT). A nonfunctioning adrenal incidentaloma (NFAI) usually requires regular follow-up; however, adrenalectomy may be necessary in certain patients. This study aimed to evaluate prognostic predictors to guide the treatment approach for AIs.</p></div><div><h3>Methods</h3><p>This retrospective, single-center study involved patients diagnosed with NFAI from January 2000 to December 2020. Patients were divided into surgery and observation groups. A subgroup analysis compared malignant and benign adenoma within the surgery group.</p></div><div><h3>Results</h3><p>A total of 307 patients were included, with 127 in the surgery group and 180 in the observation group. The surgery group displayed distinct morphological and malignant potential features in CT scans more frequently than the observational group did. The malignant subgroup exhibited more irregular borders on CT, and a higher number of patients with absolute washout under 60 % and relative washout under 40 % compared with the benign adenoma subgroup. Interestingly, within the surgery group, the mean tumor size was &lt;4 cm for the both malignant and benign adenoma subgroups.</p></div><div><h3>Conclusions</h3><p>Characterizing NFAI is important for appropriate treatment, as not all AIs have a favorable prognosis. CT findings associated with malignant potential, such as Hounsfield unit and washout values, were useful in determining the need for surgical treatment. However, the conventional criterion of a 4-cm size threshold for surgery was not a reliable malignancy predictor. Surgical resection should be considered for specific patient groups to ensure proper treatment over mere observation.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radioactive iodine ablation therapy reduces the risk of recurrent disease in pediatric differentiated thyroid carcinoma","authors":"Eman Toraih ,&nbsp;Alyssa Webster ,&nbsp;Eric Pineda ,&nbsp;Dylan Pinion ,&nbsp;Lily Baer ,&nbsp;Emily Persons ,&nbsp;Marcela Herrera ,&nbsp;Mohammad Hussein ,&nbsp;Emad Kandil","doi":"10.1016/j.suronc.2024.102120","DOIUrl":"10.1016/j.suronc.2024.102120","url":null,"abstract":"<div><h3>Background</h3><p>While radioactive iodine (RAI) therapy in older adults with differentiated thyroid carcinoma (DTC) reduces recurrence, data in pediatrics remain limited. We conducted a meta-analysis to quantify outcomes and recurrence risk with RAI versus thyroidectomy alone in the pediatric population.</p></div><div><h3>Methods</h3><p>Systematic literature review identified 34 retrospective studies including 2913 DTC patients under age 22 years (published 2005–2023). Meta-analysis calculated pooled rates of disease persistence and recurrence. Relative risk ratios compared odds of recurrence with RAI versus no RAI.</p></div><div><h3>Results</h3><p>Patients had mean age 14.7 years (95 % CI, 14.2–15.2) and were 75.9 % female (95 % CI, 73.8–78.1 %). Majority (90.2 %) received RAI. Pooled persistence rate was 30.3 % (95 % CI, 21.7–39.5 %); higher with RAI (31.5 %; 95 % CI, 22.4–41.3 %) than no RAI (4.5 %; 95 % CI, 0.0–18.7 %) (OR 3.28; 95 % CI,1.82–5.91; <em>p</em> &lt; 0.001). Recurrence rate was 8.97 % (95 % CI, 4.78–14.3 %). Those with RAI had 53.1 % lower recurrence risk versus no RAI (RR 0.47; 95 % CI, 0.27–0.82; <em>p</em> = 0.007). Median follow-up was 7.2 years (95 % CI, 5.8–8.5 years), with no association between follow-up duration and recurrence (r = −0.053; <em>p</em> = 0.80).</p></div><div><h3>Conclusions</h3><p>RAI therapy as an adjunct to thyroidectomy is associated with a significantly lower risk of long-term recurrence in pediatric DTC. These findings advocate for the use of RAI in preventing recurrence among high-risk pediatric patients with DTC.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960740424000884/pdfft?md5=5cace831bce1f904f8d97ea8774e45e1&pid=1-s2.0-S0960740424000884-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141997802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}